# TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs

> **NCT07748728** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Hangzhou Highlightll Pharmaceutical Co., Ltd** · enrollment: 90 (estimated)

## Conditions studied

- Rheumatoid Arthritis (RA)

## Interventions

- **DRUG:** TLL-018
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07748728
- **Lead sponsor:** Hangzhou Highlightll Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-09-18
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07748728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07748728, "TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07748728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*